Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2025-02-10 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a letter from AstraZeneca Pharma India Limited addressed to stock exchanges (BSE and NSE) disclosing receipt of a warning letter from the National Stock Exchange of India Limited. The letter references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of material events. The content includes details of the warning letter regarding non-compliance with quorum requirements for an audit committee meeting. The document is a regulatory disclosure about a compliance issue and includes the warning letter as an annexure. It does not contain financial statements, management discussion, or detailed report data. The document is short (4347 characters) and serves as a formal regulatory announcement of the warning letter received, not a full report or audit document. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance disclosures and regulatory announcements that do not fit other specific categories.
2025-02-10 English
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Legal Proceedings Report Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges (BSE and NSE) regarding a legal matter involving the company. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content details the dismissal of a writ petition by the company in a court case and the company's ongoing evaluation of legal options. It includes an annexure with specifics about the litigation and financial implications. The document is not a full report, financial statement, or earnings release, but rather a regulatory announcement about a legal proceeding. It fits the category of Legal Proceedings Report (LTR) as it updates on significant lawsuits involving the company.
2025-01-21 English
General Updates
Legal Proceedings Report Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about a legal proceeding outcome (dismissal of a writ petition) and the company's next steps. It includes details of the litigation and financial implications but does not contain financial statements or detailed financial analysis. The document is addressed to stock exchanges and is a regulatory announcement about legal proceedings. It fits the category of Legal Proceedings Report (LTR) as it updates on significant lawsuits and legal matters involving the company.
2025-01-21 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-01-20 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about an upcoming Board of Directors meeting scheduled for February 11, 2025. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2024. The document also mentions the closure of the trading window for insiders. The document is short (1506 characters) and serves as a notification of a future event rather than containing any financial data or results itself. It does not contain actual financial statements or detailed analysis, nor is it a report or transcript. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-01-20 English
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 ,inter alia, to consider and approve This is to inform ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about an upcoming Board of Directors meeting scheduled for February 11, 2025. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2024. The document also mentions the closure of the trading window for insiders. The document is short (1506 characters) and serves as a notification of a future event rather than containing any financial data or results itself. It does not contain actual financial statements or detailed financial analysis. Therefore, it is an announcement related to board meeting scheduling and financial results approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement and notification to exchanges.
2025-01-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.